Pipeline Watch: Phase III Readouts For Daprodustat, Delafloxacin And Venetoclax
Executive Summary
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
You may also be interested in...
Finance Watch: VC Mega-Deals Launch Biopharma Firms With New Takes On CV, Genetic Diseases
Anthos premiers with $250m from Blackstone and cardiovascular disease assets and expertise from Novartis, while Maze brings in $191m for drugs that target gene modifiers. In public company financings, Sage raises $575m ahead of Zulresso approval decision.
GenSight Sees Positives In Pivotal RESCUE Trial, Despite Missing Primary Endpoint
The company's gene therapy didn't hit the primary endpoints in either of its two Phase III studies in a severe genetic retinal disease reported so far, but a third trial designed through a special protocol assessment with the US FDA is ongoing.
AZ/FibroGen's Roxadustat Superior To Epoetin-Alfa In Chronic Renal Disease With Anemia
Positive top-line Phase III data from five studies, including the finding of superior efficacy to epotin-alfa, puts roxadustat in the driving seat as a new class of anemia agents heads toward the marketplace, but cardiovascular safety needs confirming.